Daniela Melchiorri


Titolo Pubblicato in Anno
Alzheimer's disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy? FRONTIERS IN PHARMACOLOGY 2023
The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements ESMO OPEN 2021
Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: Regulatory aspects ESMO OPEN 2020
Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease THE ONCOLOGIST 2020
Revocation of the conditional marketing authorisation of a cancer medicine: the olaratumab experience EUROPEAN JOURNAL OF CANCER 2019
European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy ESMO OPEN 2019
Optimising bench science to withstand regulatory scrutiny PHARMACOLOGICAL RESEARCH 2019
Targeting metabotropic glutamate receptors in the treatment of primary brain tumors CURRENT OPINION IN PHARMACOLOGY 2018
European medicines agency approval summary: zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer ESMO OPEN 2017
Implementing quality by design for biotech products: are regulators on track? MABS 2015

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma